COVID-19 Vaccines: india's role in global health security & future preparedness

The COVID-19 pandemic was a watershed moment for global health, catalyzing unprecedented scientific collaboration and innovation. At the heart of the global response was the rapid development and deployment of vaccines, a testament to human ingenuity and a critical tool in mitigating the virus’s devastating impact. This article analyzes the science behind these vaccines, India’s strategic role in their distribution, and the evolving global framework for pandemic preparedness.

The Science of Immunity: How Vaccines Work

Vaccines work by introducing a harmless piece of a pathogen, or instructions to build that piece, into the body. This triggers the innate and acquired immune systems without causing disease. The immune system, particularly through humoral (B-cell) and cell-mediated (T-cell) responses, creates memory cells. If the body encounters the actual virus later, these memory cells mount a swift and powerful defense.

The development of COVID-19 vaccines saw the deployment of several cutting-edge and traditional technologies.

Fun Fact: The concept of inoculation has ancient roots. Evidence suggests that as early as the 10th century, the Chinese practiced a form of variolation by inhaling dried and ground smallpox scabs to build immunity.

Mnemonic for Key Vaccine Types: Remember the main platforms with the phrase “My Very Important Shield” - for mRNA, Viral Vector, Inactivated, and Subunit.

India: The ‘Pharmacy of the World’ in Action

India’s robust pharmaceutical industry played a pivotal role during the pandemic. Leveraging its massive manufacturing capacity, the nation not only launched one of the world’s largest domestic vaccination drives but also emerged as a key global supplier.

• Hyderabad - The Vaccine Capital: The city of Hyderabad became a global hub, housing major manufacturers like Bharat Biotech (developer of Covaxin) and the Biological E. (developer of Corbevax). The Serum Institute of India (SII) in Pune, the world’s largest vaccine manufacturer, was critical in producing the Oxford-AstraZeneca vaccine as Covishield.

• Vaccine Maitri Initiative: India’s ambitious diplomatic program, ‘Vaccine Maitri’ (Vaccine Friendship), supplied over 300 million vaccine doses to more than 100 countries, bolstering its reputation as a reliable global health partner. This act of health diplomacy was crucial in providing access to low- and middle-income nations.

Captivating Stat: At its peak, the Serum Institute of India was reportedly producing over 2.5 million doses of Covishield per day, showcasing an incredible manufacturing scale.

The Evolving Threat: Post-2024 Developments and Global Policy

The fight against COVID-19 did not end with the first wave of vaccines. The virus continues to evolve, necessitating updated strategies and a stronger global framework.

• Updated Vaccines for New Variants: Scientific focus has shifted to tackling new viral lineages. For the 2025-2026 season, regulatory bodies approved updated vaccines from Moderna, Pfizer, and Novavax targeting the JN.1 variant, which became the dominant global strain. This highlights a long-term strategy of periodic vaccine updates, similar to the annual flu shot.

• The WHO Pandemic Agreement (2025): A landmark development was the formal adoption of the WHO Pandemic Agreement in May 2025. After intense negotiations, this legally binding accord aims to prevent a repeat of the chaotic and inequitable response seen in 2020. Its core pillars include strengthening the “One Health” approach (linking human, animal, and environmental health), ensuring equitable access to medical countermeasures through a Pathogen Access and Benefit-Sharing (PABS) system, and enhancing global supply chain coordination. Crucially, the agreement respects national sovereignty and does not grant the WHO power to impose lockdowns or vaccine mandates.

Analogy: Think of the new Pandemic Agreement as a global fire department. Before, each country had its own fire brigade, and they argued over who owned the water while the fire raged. Now, they’ve agreed on a plan to share resources and fight the fire together as soon as it starts.

Critical Policy Appraisal

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis

The legal framework for vaccine regulation and pandemic management in India is primarily rooted in the Drugs and Cosmetics Act, 1940 (governing vaccine approval and quality) and the Epidemic Diseases Act, 1897 (granting special powers to governments to control epidemics). The National Health Mission serves as the overarching vehicle for implementing public health programs, including immunization.

UPSC Integration: Connecting the Dots

• GS Paper 2 (Polity & Governance, IR): The topic directly relates to cooperative federalism (Centre-State coordination), health as a state subject, and India’s foreign policy objectives through health diplomacy. The WHO Pandemic Agreement is a key topic in international bodies.
• GS Paper 3 (Economy, S&T): It connects to the Indian pharmaceutical industry’s capacity, Intellectual Property Rights (debates over TRIPS waivers for vaccines), supply chain management, and advancements in biotechnology (mRNA, viral vectors).
• GS Paper 4 (Ethics): The principle of equity in vaccine distribution, ethical considerations in clinical trials, and the responsibility of governments and corporations in a public health crisis are relevant ethical dimensions.

Expert Analysis: Future Impact

The COVID-19 pandemic has permanently altered the landscape of global health security. The success of mRNA platforms has unlocked a new frontier in medicine, with potential applications for cancer, autoimmune diseases, and other infectious diseases. For India, the crisis was both a challenge and an opportunity. It exposed weaknesses in the public health system but also showcased its immense manufacturing strength. The key long-term challenge is translating this manufacturing prowess into R&D leadership. The policy focus must now shift from crisis management to building resilient health infrastructure, investing in genomic surveillance, and cementing India’s role as a leader in the new global health architecture defined by the Pandemic Agreement.

Prelims Practice Question (MCQ)

Question: With reference to vaccine technologies, how does a viral vector vaccine like Covishield (Oxford-AstraZeneca) work? a) It introduces a weakened form of the live SARS-CoV-2 virus into the body. b) It uses a harmless, modified virus to deliver the genetic code for the SARS-CoV-2 spike protein. c) It directly injects purified spike proteins of the SARS-CoV-2 virus. d) It delivers messenger RNA (mRNA) that instructs human cells to produce the spike protein.

Answer: (b) Explanation: Viral vector vaccines use a different, harmless virus (in the case of Covishield, a chimpanzee adenovirus) as a transport mechanism, or ‘vector,’ to carry the genetic instructions for producing the spike protein of the SARS-CoV-2 virus into human cells. This allows the body to produce the spike protein and develop an immune response without any exposure to the actual coronavirus. Option (a) describes a live attenuated vaccine, (c) describes a subunit vaccine, and (d) describes an mRNA vaccine.

Mains Sample Question

Question: Critically analyze India’s ‘Vaccine Maitri’ initiative as a tool of health diplomacy. Discuss the challenges and opportunities it presents for India’s global standing in a post-pandemic world. (15 Marks, 250 Words)

Mind Map Outline (Revision Structure)

• COVID-19 Vaccines & Global Health
  • Fundamentals of Immunity
    • Innate vs. Acquired Immunity
    • Humoral (B-cell) and Cell-Mediated (T-cell) Response
  • Vaccine Technology & Platforms
    • mRNA Vaccines
      • Mechanism: Genetic code for spike protein
      • Examples: Pfizer, Moderna
    • Viral Vector Vaccines
      • Mechanism: Harmless virus as a carrier
      • Examples: Covishield, Sputnik V
    • Inactivated Vaccines
      • Mechanism: Killed virus
      • Examples: Covaxin
    • Subunit Vaccines
      • Mechanism: Purified viral proteins
      • Examples: Covovax
  • India’s Role in the Pandemic
    • Manufacturing Hub (“Pharmacy of the World”)
      • Serum Institute of India (Covishield)
      • Bharat Biotech (Covaxin)
      • Hyderabad as “Vaccine Capital”
    • Health Diplomacy
      • Vaccine Maitri Initiative: Scope and Impact
  • Policy, Governance & Future Preparedness
    • Domestic Legal Framework
      • Drugs and Cosmetics Act, 1940
      • Epidemic Diseases Act, 1897
    • Global Health Architecture
      • WHO Pandemic Agreement (May 2025)
        • Core Goals: Equity, One Health, PABS System
        • Respect for National Sovereignty
      • COVAX Facility
    • Ongoing Challenges
      • Vaccine Equity and Nationalism
      • Logistics and Cold Chain Management
      • Misinformation and Vaccine Hesitancy
    • Post-2024 Developments
      • Updated vaccines for new variants (e.g., JN.1)